

Special Issue

Molecular Immunotherapy of Solid Tumors

Message from the Guest Editor

Cancer immunotherapy is transforming multidisciplinary cancer care and opening new therapeutic avenues. The current types of immunotherapies that have been explored include monoclonal antibodies (mAb), immune-checkpoint inhibitors (ICIs), oncolytic viral platforms (OV), cancer vaccines, adoptive cell therapy (ACT), and various combinatorial approaches. The purpose of this Special Issue is to define the role of molecular immunotherapies in solid tumors, including (1) mAb in cancer treatment; (2) the contribution of ICIs in the progress of cancer therapies; (3) cancer vaccines in solid tumors; (4) predictive biomarkers for checkpoint-inhibitor-based immunotherapy; (5) drug resistance and immunotherapies; and (6) the combination of immunotherapies with conventional cancer treatments. This Special Issue welcomes both original research articles and reviews.

Guest Editor

Dr. Raheleh Roudi

Molecular Imaging Program at Stanford, Department of Radiology,
Stanford University, Stanford, CA 94305, USA

Deadline for manuscript submissions

closed (15 August 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/133740

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)